美罗华结合环磷酰胺免疫抑制治疗系统红斑狼疮的效果研究  

作　　者：陈建英[1] 

机构地区：[1]湖南省人民医院,湖南长沙410000

出　　处：《湖南中医药大学学报》2016年第A02期1426-1426,共1页Journal of Hunan University of Chinese Medicine

摘　　要：目的：本文就美罗华结合环磷酰胺免疫抑制治疗系统红斑狼疮临床效果进行分析与探讨.方法：抽取我院 2013年4月 -2015年4月期间收治的64例系统性红斑狼疮患者,按照抽签法将其分为实验组（n=32）与参照组（n=32）,参照组给予美罗华单药治疗,实验组患者在此基础上加用小剂量环磷酰胺治疗,对比其治疗总有效率及不良反应.结果：经不同治疗方法后,实验组中1例无效,参照组中7例无效,实验组患者的治疗总有效率96.88%显著高于参照组78.13%,卡方检验结果显示P〈0.05,在治疗期间,两组患者均未出现较为严重的不良反应,所出现的不适症状均可耐受.实验组患者的不良反应发生率 12.50% 与参照组 9.38%对比,无明显差异,卡方检验结果显示 P〉0.05.参照组三项值（1.51±0.11、1.33±0.07、1.37±0.11）和实验组（1.07±0.05、1.00±0.04、1.01±0.08）相比差异均具有统计学意义（P〈0.05）.结论：对系统性红斑狼疮患者给予美罗华联合小剂量环磷酰胺治疗具有显著效果,且无严重不良反应,具有重要的临床实践价值.The rituximab combined with cyclophosphamide immune suppression in the treatment of systemic lupus erythematosus （SLE） clinical effect are analyzed and discussed. Methods： selected in our hospital from April 2013 and 2015 during April were 64 cases of system lupus lupus patients, according to the draw approach will be the experimental group （n = 32） and the reference group （n = 32）, the reference group given rituximab monotherapy, added with a small dose of cyclophosphamide in the treatment of patients in the experimental group on the basis of this, comparing the total effective rate and adverse reaction. Results： after different treatment approachs, experimental group 1 cases ineffective, with reference to the group of 7 cases were invalid, treatment of patients in the experimental group the total efficiency of 96.88%, significantly higher than the reference group 78.13%, chi square test outcomings show that the P 〈 0.05, at the end of the treatment period, patients in the two groups did not appear serious adverse reactions, the discomfort symptoms can be tolerated. The incidence of adverse reactions in the experimental group was 12.50% compared with the reference group 9.38%, no significant difference, the chi square test outcomings showed P〉0.05. The three values of reference group （1.51 ＋ 0.11, 1.33 ＋ 0.07, 1.37 ＋ 0.11） and experimental group （1.07 ＋ 0.05, 1 ＋ 0.04, 1.01 ＋ 0.08） were statistically significant （P〈0.05）. Conclusion： in patients with systemic lupus erythematosus （SLE） give rituximab combined with low dose cyclophosphamide therapy has a significant effect and no serious adverse reactions, with important clinical practice value.

关 键 词：美罗华 环磷酰胺 免疫抑制 系统红斑狼疮 

分 类 号：R2[医药卫生—中医学]